Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mahmoud Chehab

Urology Syracuse, NY Medical Doctor

NPI 1093005597 CMS profile 3460849

750 E Adams St, Syracuse, NY 13210

Open in the dashboard

General payments

$2,236

19 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mahmoud Chehab of Syracuse, NY is reported in the CMS Open Payments database as having received $2,236 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $774 8
2023 General $83 2
2021 General $83 2
2020 General $65 1
2019 General $1,231 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahmoud Chehab
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Mahmoud Chehab were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Mahmoud Chehab Urology median Middle half National median
2019 $1,231 $480 $147–$1,201 $163
2020 $65 $246 $87–$645 $114
2021 $83 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $83 $560 $168–$1,461 $160
2024 $774 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. NeoTract Inc. $1,196 4 payments
  2. PROCEPT BioRobotics Corporation $686 7 payments
  3. Boston Scientific Corporation $142 3 payments
  4. Cook Medical LLC $88 1 payment
  5. Teleflex LLC $64 1 payment
  6. Urogen Pharma, Inc. $26 1 payment
  7. TissueTech, Inc. $19 1 payment
  8. Astellas Pharma US Inc $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $1,322 6 payments
  2. Food and Beverage $915 13 payments
Products named General payments · program years 2019–2024
  1. UROLIFT $1,196 4 payments
  2. AQUABEAM SYSTEM $686 7 payments
  3. Cook $88 1 payment
  4. SPACEOAR $65 1 payment
  5. UroLift System $64 1 payment
  6. LithoVue $57 1 payment
  7. JELMYTO $26 1 payment
  8. SOLYX $20 1 payment
  9. NEOX $19 1 payment
  10. CLARIX $19 1 payment
  11. Other $30 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

645

Median for Urology: 1,053

Drug cost

$64,673

Median for Urology: $101,464

Branded share of claims

21.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 43 $28,404
Gemtesa Vibegron Brand 43 $27,338
Trospium Chloride Generic 64 $3,227
Tamsulosin Hcl Generic 180 $2,135
Tolterodine Tartrate Er Tolterodine Tartrate Brand 17 $1,410
Finasteride Generic 72 $846
Solifenacin Succinate Generic 35 $774
Cephalexin Generic 129 $322
Ciprofloxacin Hcl Generic 29 $112
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 33 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$206,366

Of which drugs: $22,359

Medicare patients

586

Average age 74

Services billed

3,288

153 women, 433 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 31%
Cancer 31%
Ischemic heart disease 29%
Chronic kidney disease 27%
COPD 25%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 19 155 $21,181

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record